3-Ethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine, 95.0%, 10g

(S)-2-(4-Chlorophenyl)-3-methylbutanoic acid, 95.0%, 1g

2-(N-BOC-AMINOMETHYL)AZETIDINE, 95.0%, 1g

3-Bromomethyl-cyclobutanecarboxylic acid methyl ester, 98%, 5g

Lauroyl Chloride>98.0%(GC)25mL

(Z)-3-(METHOXYCARBONYL)-4-(PYRIDIN-3-YL)BUT-3-ENOIC ACID, 95%, 250mg

1-(4-(Benzyloxy)-6-chloro-2-methoxypyridin-3-yl)ethan-1-one, 97%, 250mg

8-(3-methoxyphenyl)-8-oxooctanenitrile, 97.0%, 5g

(5-Chloro-1H-benzo[d]imidazol-2-yl)methanamine, 98%, 1g

E-Plan phase EPLPHi 20x/0.40 infinity corrected IOS objective. Working distance 2.61 mm

4-(6-Methoxypyridin-3-yl)benzoic acid, 95.0%, 10g

Ethyl 2-methylpent-4-enoate, 98% +(stabilized with 0.2% ��-tocopherol), 25g

4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-6-(3-methyl-2-butenyl)-, (2S)-, 1g